FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2339274021> ?p ?o ?g. }

• W2339274021 abstract "BACKGROUND: The phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase (MGMT) non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ). BEV/IRI prolonged progression-free survival but overall survival (OS) was similar in both arms. To identify subpopulations with a particularly favourable course, we assessed the prognostic potential of magnetic resonance imaging (MRI) markers at baseline and during the first 4 months of treatment. METHODS: MRIs at baseline, 8, and 16 weeks after therapy initiation were analyzed for T1-hyperintense and diffusion-restricted lesions, contrast-enhancing lesions qualifying for tumor progression (25% increase), and progression of Fluid-attenuated inversion recovery (FLAIR) hyperintense lesions. The MRI findings were correlated with survival. RESULTS: None of the baseline parameters was prognostic in the entire cohort or predictive in the BEV/IRI arm. The presence of diffusion-restricted lesions was neither prognostic nor predictive of BEV/IRI benefit at any timepoint. At 8 weeks of follow-up, 49 patients developing a new combined diffusion-restricted and T1-hyperintense lesion had significantly greater OS than 90 patients without such changes (median OS, 17.5 vs. 15.7 months, p = 0.003). This effect was significant in the BEV/IRI arm (median OS, 17.2 vs. 15.7 months, p = 0.026) whereas significance was narrowly missed in the TMZ arm (median, 18.0 vs. 14.8 months, p = 0.071). At 16 weeks, OS in BEV/IRI-treated patients experiencing exclusively progressive FLAIR hyperintensities (17 of 52 evaluable patients; median OS, 17.5 months) was no worse than in BEV/IRI-treated patients with no progression on FLAIR and T1-weighted contrast-enhancing images (median OS, 19.4 months). In contrast, patients with progressive contrast-enhancing lesions had significantly shorter OS (median, 14.3 months, p = 0.0003, logrank test). CONCLUSIONS: The development of combined T1-hyperintense and diffusion-restricted lesions in early follow-up MRIs is associated with improved OS, particularly in BEV/IRI-treated patients. FLAIR-only progression does not appear to be predictive of a worse outcome with BEV/IRI treatment." @default.
• W2339274021 created "2016-06-24" @default.
• W2339274021 creator A5000588528 @default.
• W2339274021 creator A5001167896 @default.
• W2339274021 creator A5005840478 @default.
• W2339274021 creator A5008640562 @default.
• W2339274021 creator A5018453143 @default.
• W2339274021 creator A5019276321 @default.
• W2339274021 creator A5023052042 @default.
• W2339274021 creator A5031780975 @default.
• W2339274021 creator A5032459039 @default.
• W2339274021 creator A5040462911 @default.
• W2339274021 creator A5042490774 @default.
• W2339274021 creator A5051435963 @default.
• W2339274021 creator A5059953951 @default.
• W2339274021 creator A5066290988 @default.
• W2339274021 creator A5074321110 @default.
• W2339274021 creator A5076567865 @default.
• W2339274021 creator A5091909249 @default.
• W2339274021 date "2015-11-01" @default.
• W2339274021 modified "2023-09-27" @default.
• W2339274021 title "NIMG-41MRI FINDINGS IN THE GLARIUS TRIAL: PROGNOSTIC AND PREDICTIVE IMPLICATIONS" @default.
• W2339274021 doi "https://doi.org/10.1093/neuonc/nov225.41" @default.
• W2339274021 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4639064" @default.
• W2339274021 hasPublicationYear "2015" @default.
• W2339274021 type Work @default.
• W2339274021 sameAs 2339274021 @default.
• W2339274021 citedByCount "0" @default.
• W2339274021 crossrefType "journal-article" @default.
• W2339274021 hasAuthorship W2339274021A5000588528 @default.
• W2339274021 hasAuthorship W2339274021A5001167896 @default.
• W2339274021 hasAuthorship W2339274021A5005840478 @default.
• W2339274021 hasAuthorship W2339274021A5008640562 @default.
• W2339274021 hasAuthorship W2339274021A5018453143 @default.
• W2339274021 hasAuthorship W2339274021A5019276321 @default.
• W2339274021 hasAuthorship W2339274021A5023052042 @default.
• W2339274021 hasAuthorship W2339274021A5031780975 @default.
• W2339274021 hasAuthorship W2339274021A5032459039 @default.
• W2339274021 hasAuthorship W2339274021A5040462911 @default.
• W2339274021 hasAuthorship W2339274021A5042490774 @default.
• W2339274021 hasAuthorship W2339274021A5051435963 @default.
• W2339274021 hasAuthorship W2339274021A5059953951 @default.
• W2339274021 hasAuthorship W2339274021A5066290988 @default.
• W2339274021 hasAuthorship W2339274021A5074321110 @default.
• W2339274021 hasAuthorship W2339274021A5076567865 @default.
• W2339274021 hasAuthorship W2339274021A5091909249 @default.
• W2339274021 hasBestOaLocation W23392740211 @default.
• W2339274021 hasConcept C101070640 @default.
• W2339274021 hasConcept C126322002 @default.
• W2339274021 hasConcept C126838900 @default.
• W2339274021 hasConcept C143409427 @default.
• W2339274021 hasConcept C143998085 @default.
• W2339274021 hasConcept C146638467 @default.
• W2339274021 hasConcept C2776694085 @default.
• W2339274021 hasConcept C2777389519 @default.
• W2339274021 hasConcept C2777802072 @default.
• W2339274021 hasConcept C2780739268 @default.
• W2339274021 hasConcept C70816921 @default.
• W2339274021 hasConcept C71924100 @default.
• W2339274021 hasConcept C72563966 @default.
• W2339274021 hasConceptScore W2339274021C101070640 @default.
• W2339274021 hasConceptScore W2339274021C126322002 @default.
• W2339274021 hasConceptScore W2339274021C126838900 @default.
• W2339274021 hasConceptScore W2339274021C143409427 @default.
• W2339274021 hasConceptScore W2339274021C143998085 @default.
• W2339274021 hasConceptScore W2339274021C146638467 @default.
• W2339274021 hasConceptScore W2339274021C2776694085 @default.
• W2339274021 hasConceptScore W2339274021C2777389519 @default.
• W2339274021 hasConceptScore W2339274021C2777802072 @default.
• W2339274021 hasConceptScore W2339274021C2780739268 @default.
• W2339274021 hasConceptScore W2339274021C70816921 @default.
• W2339274021 hasConceptScore W2339274021C71924100 @default.
• W2339274021 hasConceptScore W2339274021C72563966 @default.
• W2339274021 hasLocation W23392740211 @default.
• W2339274021 hasLocation W23392740212 @default.
• W2339274021 hasOpenAccess W2339274021 @default.
• W2339274021 hasPrimaryLocation W23392740211 @default.
• W2339274021 hasRelatedWork W1575333877 @default.
• W2339274021 hasRelatedWork W1575933248 @default.
• W2339274021 hasRelatedWork W1967894039 @default.
• W2339274021 hasRelatedWork W1991445985 @default.
• W2339274021 hasRelatedWork W1997772604 @default.
• W2339274021 hasRelatedWork W2023179262 @default.
• W2339274021 hasRelatedWork W2049335250 @default.
• W2339274021 hasRelatedWork W2057270593 @default.
• W2339274021 hasRelatedWork W2067901299 @default.
• W2339274021 hasRelatedWork W2088411836 @default.
• W2339274021 hasRelatedWork W2101177013 @default.
• W2339274021 hasRelatedWork W2159103156 @default.
• W2339274021 hasRelatedWork W2170373633 @default.
• W2339274021 hasRelatedWork W2258341481 @default.
• W2339274021 hasRelatedWork W2328710344 @default.
• W2339274021 hasRelatedWork W2338244337 @default.
• W2339274021 hasRelatedWork W2412278317 @default.
• W2339274021 hasRelatedWork W2790109126 @default.
• W2339274021 hasRelatedWork W2936001065 @default.
• W2339274021 hasRelatedWork W3207354923 @default.
• W2339274021 isParatext "false" @default.
• W2339274021 isRetracted "false" @default.
• W2339274021 magId "2339274021" @default.

• next